Skip to content
Austin Top 50
Author:
BridgeBio Pharma, Inc.
BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates
May 7, 2026
BridgeBio to Participate in May and June Investor Conferences
May 6, 2026
BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil
May 6, 2026
BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE
May 5, 2026
BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026
May 4, 2026
BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET
April 30, 2026
BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. White
April 28, 2026
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 20, 2026
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9
March 11, 2026
←
Previous Page
1
2
3
4